Lyra Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Lyra Therapeutics, Inc. | LYRA - NASDAQ |
$14.00-$16.00 | $16.00 | $21.00 | 3.5 million | 5/1/2020 |
| BofA Securities, Jefferies, William Blair | ||||||
Co-Manager(s): BTIG | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-03-06 Terms Added 2020-04-27 | ||||||
Lyra Therapeutics, Inc. Quote & Chart - Click for current quote - LYRA
IPO Boutique aggregates information on public companies and private companies, such as "LYRA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Lyra Therapeutics, Inc. (adapted from Lyra Therapeutics, Inc. prospectus):
They are a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "LYRA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.